tbuckley/cabot-search huggingface dataset:
HER3 Is an Actionable Target in Advanced Prostate Cancer
Authors: Veronica Gil, Susana Miranda, Ruth Riisnaes, Bora Gurel, Mariantonietta D’Ambrosio, Alessandro Vasciaveo, Mateus Crespo, Ana Ferreira, Daniela Brina, Martina Troiani, Adam Sharp, Beshara Sheehan, Rossitza Christova, George Seed, Ines Figueiredo, Maryou Lambros, David Dolling, Jan Rekowski, Abdullah Alajati, Matthew Clarke, Rita Pereira, Penny Flohr, Gemma Fowler, Gunther Boysen, Semini Sumanasuriya, Diletta Bianchini, Pasquale Rescigno, Caterina Aversa, Nina Tunariu, Christina Guo, Alec Paschalis, Claudia Bertan, Lorenzo Buroni, Jian Ning, Suzanne Carreira, Paul Workman, Amanda Swain, Andrea Califano, Michael M. Shen, Andrea Alimonti, Antje Neeb, Jonathan Welti, Wei Yuan, Johann de Bono
Journal: Cancer Research (2021)

Abstract It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 protein is commonly highly expressed in lethal prostate cancer, associating with reduced time to castration resistance (CR) and survival. Multiplex immunofluorescence indicated that the HER3 ligand NRG1 is detectable primarily in tumor-infiltrating myelomonocytic cells in human prostate cancer; this observation was confirmed using single-cell RNA sequencing of human prostate cancer biopsies and murine transgenic prostate cancer models. In castration-resistant prostate cancer (CRPC) patient-derived xenograft organoids with high HER3 expression as well as mouse prostate cancer organoids, recombinant NRG1 enhanced proliferation and survival. Supernatant from murine bone marrow–derived macrophages and myeloid-derived suppressor cells promoted murine prostate cancer organoid growth in vitro, which could be reversed by a neutralizing anti-NRG1 antibody and ERBB inhibition. Targeting HER3, especially with the HER3-directed antibody–drug conjugate U3-1402, exhibited antitumor activity against HER3-expressing prostate cancer. Overall, these data indicate that HER3 is commonly overexpressed in lethal prostate cancer and can be activated by NRG1 secreted by myelomonocytic cells in the tumor microenvironment, supporting HER3-targeted therapeutic strategies for treating HER3-expressing advanced CRPC. Significance: HER3 is an actionable target in prostate cancer, especially with anti-HER3 immunoconjugates, and targeting HER3 warrants clinical evaluation in prospective trials.
Surgical fixation with K-wires versus casting in adults with fracture of distal radius: DRAFFT2 multicentre randomised clinical trial
Authors: Matthew L Costa, Juul Achten, Alexander Ooms, May Ee Png, Jonathan A Cook, Sarah E Lamb, Helen Hedley, Joseph Dias
Journal: BMJ (2022)

To assess wrist function, quality of life, and complications in adult patients with a dorsally displaced fracture of the distal radius, treated with either a moulded cast or surgical fixation with K-wires. Multicentre randomised clinical superiority trial, SETTING: 36 hospitals in the UK National Health Service (NHS). 500 adults aged 16 or over with a dorsally displaced fracture of the distal radius, randomised after manipulation of their fracture (255 to moulded cast; 245 to surgical fixation). Manipulation and moulded cast was compared with manipulation and surgical fixation with K-wires plus cast. Details of the application of the cast and the insertion of the K-wires were at the discretion of the treating surgeon, according to their normal clinical practice. The primary outcome measure was the Patient Rated Wrist Evaluation (PRWE) score at 12 months (five questions about pain and 10 about function and disability; overall score out of 100 (best score=0 and worst score=100)). Secondary outcomes were PRWE score at three and six months, quality of life, and complications, including the need for surgery due to loss of fracture position in the first six weeks. The mean age of participants was 60 years and 417 (83%) were women; 395 (79%) completed follow-up. No statistically significant difference in the PRWE score was seen at 12 months (cast group (n=200), mean 21.2 (SD 23.1); K-wire group (n=195), mean 20.7 (22.3); adjusted mean difference -0.34 (95% confidence interval -4.33 to 3.66), P=0.87). No difference was seen at earlier time points. In the cast group, 33 (13%) of participants needed surgical fixation for loss of fracture position in the first six weeks compared with one revision surgery in the K-wire group (odds ratio 0.02, 95% confidence interval 0.001 to 0.10). Among patients with a dorsally displaced distal radius fracture that needed manipulation, surgical fixation with K-wires did not improve patients' wrist function at 12 months compared with a cast. ISRCTN registry ISRCTN11980540.
Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device; Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure; Increase in Left Ventricular Assist Device Thrombosis
Journal: New England Journal of Medicine (2018)

Correction from The New England Journal of Medicine — Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device; Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure; Increase in Left Ventricular Assist Device Thrombosis
International Comments
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Does SARS-CoV-2 Infect the Kidney?
Authors: Shaza Khan, Lihe Chen, Chin-Rang Yang, Viswanathan Raghuram, Syed J. Khundmiri, Mark A. Knepper
Journal: Journal of the American Society of Nephrology (2020)

Podcast This article contains a podcast at https://www.asn-online.org/media/podcast/JASN/2020_11_24_JASN2020081229.mp3
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Authors: Yoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, Do-Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik-Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen-Shi Chen, Li-Yuan Bai, Sung-Yong Oh, Yasuhiro Choda, Hisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara, Narikazu Boku
Journal: The Lancet Oncology (2022)
Modification of HERG channel properties under conditions of simulated myocardial ischemia Bruce D. Walker, Hui Tie, Cameron B. Singleton, Jane A. Bursill, Ken R. Wyse, Asne R. Bauskin, Stella M. Valenzuela, Wan Wu, Samuel N. Breit, Terence J. Campbell. St Vincent's Hospital, Sydney, Australia
Journal: Journal of the American College of Cardiology (2001)
Cancer Research, Chicago
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical management in hospitals.
Journal: BMJ (1967)

In December 1965 the Secretary of State for Scotland set up a Working Party of doctors and hospital service administrators "to consider what developments in the hospital service are desirable in order to promote efficiency in the organization of medical work."In 1966 a 7oint Working Party was appointed by the Ministry of Health and the 7oint Consultants' Committee with the same terms of reference.The two Working Parties have published
Matrix stiffness exacerbates the proinflammatory responses of vascular smooth muscle cell through the DDR1-DNMT1 mechanotransduction axis
Authors: Jin Wang, Si-an Xie, Ning Li, Tao Zhang, Weijuan Yao, Hucheng Zhao, Wei Pang, Lili Han, Jiayu Liu, Jing Zhou
Journal: Bioactive Materials (2022)

Vascular smooth muscle cell (vSMC) is highly plastic as its phenotype can change in response to mechanical cues inherent to the extracellular matrix (ECM). VSMC may be activated from its quiescent contractile phenotype to a proinflammatory phenotype, whereby the cell secretes chemotactic and inflammatory cytokines, e.g. MCP1 and IL6, to functionally regulate monocyte and macrophage infiltration during the development of various vascular diseases including arteriosclerosis. Here, by culturing vSMCs on polyacrylamide (PA) substrates with variable elastic moduli, we discovered a role of discoidin domain receptor 1 (DDR1), a receptor tyrosine kinase that binds collagens, in mediating the mechanical regulation of vSMC gene expression, phenotype, and proinflammatory responses. We found that ECM stiffness induced DDR1 phosphorylation, oligomerization, and endocytosis to repress the expression of DNA methyltransferase 1 (DNMT1), very likely in a collagen-independent manner. The DDR1-to-DNMT1 signaling was sequentially mediated by the extracellular signal-regulated kinases (ERKs) and p53 pathways. ECM stiffness primed vSMC to a proinflammatory phenotype and this regulation was diminished by DDR1 inhibition. In agreement with the in vitro findings, increased DDR1 phosphorylation was observed in human arterial stiffening. DDR1 inhibition in mouse attenuated the acute injury or adenine diet-induced vascular stiffening and inflammation. Furthermore, mouse vasculature with SMC-specific deletion of Dnmt1 exhibited proinflammatory and stiffening phenotypes. Our study demonstrates a role of SMC DDR1 in perceiving the mechanical microenvironments and down-regulating expression of DNMT1 to result in vascular pathologies and has potential implications for optimization of engineering artificial vascular grafts and vascular networks.
Spatial extent and magnitude of myocardial no-, low-reflow by contrast echocardiography after reperfusion in patients with acute coronary syndrome represent segmental and transmural extent of infarct Christian Firschke, Peter Andr�ssy, Ullrich Schricke, Jens Paliga, Markus Schwaiger, Albert Schoemig. Deutsches Herzzentrum, Technische Universitaet Muenchen, Muenchen, Germany
Journal: Journal of the American College of Cardiology (2001)
Some Concerns About Imputation Methods for Missing Data—Reply
Authors: Ryan J. Van Lieshout, Calan Savoy, Steven Hanna
Journal: JAMA Psychiatry (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
ASSOCIATION NEWS.
Authors: W. B. Atkinson
Journal: JAMA (1897)

<b>The Journal Special Train</b>will leave Chicago Sunday, May 30, over the Pennsylvania Line, direct to Philadelphia without change. <h3>Railroad Rates.</h3> —The Committee of Arrangements had several meetings for arranging the work, of which I was not advised. When accidentally learning of it I asked Dr. Hare to keep me posted that I might be able to reply to questions, and since then I have been invited to all the meetings of the Committee. But already Dr. E. E. Montgomery had been assigned to the railroad work, and had arranged with them as to the rate. This was as early as last December. Of course I did not propose to put my request before the roads till the opening of the year as they always insist that it is too early to consider such work till the year comes in. From what I can learn Dr. M., has done all
Error in Results
Authors: Alexander Acuña, Tarun Jella, Atul Kamath
Journal: JAMA Surgery (2021)

Erika L. Rangel, MD, MS; Manuel Castillo-Angeles, MD, MPH; Sarah Rae Easter, MD; Rachel B. Atkinson, MD; Ankush Gosain, MD, PhD; Yue-Yung Hu, MD; Zara Cooper, MD, MSc; Tanujit Dey, PhD; Eugene Kim, MD
Movement vigor: Frameworks, exceptions, and nomenclature
Authors: Rory John Bufacchi, Gian Domenico Iannetti
Journal: Behavioral and Brain Sciences (2021)

Shadmehr and Ahmed cogently argue that vigor of appetitive movements is positively correlated with their value, and that value can therefore be inferred by measuring vigor. Here, we highlight three points to consider when interpreting this account: (1) The correlation between vigor and value is not obligatory, (2) the vigor effect also arises in frameworks other than optimal foraging, and (3) the term vigor can be misinterpreted, thereby affecting rigor.
Improving survival prediction of patients treated with external beam radiotherapy for dysphagia in esophageal cancer using prediction models.
Authors: Steven Kuijper, Paul M. Jeene, Héctor G. van den Boorn, Sherif El Sharouni, Pètra Braam, Vera Oppedijk, Rob Verhoeven, Maarten C.C.M. Hulshof, Hanneke W.M. Van Laarhoven
Journal: Journal of Clinical Oncology (2022)

358 Background: The recently published POLDER trial investigated the effects of external beam radiotherapy (EBRT) on dysphagia caused by incurable esophageal cancer. As the effects of EBRT were presumed not to be immediate, an estimated life expectancy of minimally three months was required for inclusion. However, nearly a third of the included patients died within three months. The aim of this study was to investigate if the use of prediction models could have improved the physician’s estimation of the patient’s survival, and thus the eligibility for EBRT treatment. Methods: Data from the POLDER trial (N = 110) were linked to the Netherlands Cancer Registry to retrieve additional patient, tumor and treatment characteristics. Two published prediction models (the SOURCE model and Steyerberg model) were used to predict overall survival for all patients included in the POLDER trial. Predicted survival probabilities were dichotomized (predicted deceased/alive at three months) and the positive predictive value, negative predictive value, sensitivity, specificity and the area under the curve (AUC) were used to evaluate the predictive performance. DeLong’s test was used to test the difference between the AUCs of the SOURCE and Steyerberg models for statistical significance. Results: In the POLDER trial, 35 patients were unjustly presumed to survive three months. Predicting survival at three months, the SOURCE and Steyerberg model had an AUC of 0.76 and 0.60 respectively. The difference between the AUCs of the models was significant (p =.017). Under optimal survival cut-off scores, SOURCE would have incorrectly predicted 16 patients to survive three months. For the Steyerberg model this was 22 patients. Furthermore, using SOURCE under these cut-off scores, seven patients were incorrectly predicted to not survive three months compared to 18 patients using the Steyerberg model. Conclusions: Results showed that the SOURCE and Steyerberg models could have improved survival predictions compared to clinical judgement alone. The SOURCE model was found to be a more useful decision aid than the Steyerberg model as it was more accurate. Accepting that a small proportion of patients are incorrectly predicted not to survive three months and are not considered for EBRT treatment, we recommend using the SOURCE model for patients that are considered for palliative treatment of dysphagia caused by esophageal cancer.
Serum folate and risk of fatal coronary heart disease
Authors: R. D. Braun
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medication errors and outcomes with fixed double-bolus r-PA versus bolus plus weight-adjusted infusion t-PA fibrinolysis: The GUSTO-III experience Shaun G. Goodman, Aiala Barr, Christopher Granger, Magnus Ohman, Anatoly Langer, Paul Armstrong, Brian Gibler, Eric Topol. Canadian Heart Research Centre, Toronto, ON, Canada, Duke University Medical Center, Durham, NC
Journal: Journal of the American College of Cardiology (2001)
Different prognostic value of the oxygen-uptake and the ventilatory efficacy in the risk stratification of heart failure patients with and without chronic betablocker therapy Anselm K. Gitt, Caroline Bergmeier, Armin Schwarz, Andreas Kilkowski, Thomas Kleemann, Matthias Bangert, Jochen Senges. Herzzentrum Ludwigshafen, Ludwigshafen, Germany
Journal: Journal of the American College of Cardiology (2001)
MSCs-laden injectable self-healing hydrogel for systemic sclerosis treatment
Authors: Min Nie, Bin Kong, Guopu Chen, Ying Xie, Yuanjin Zhao, Lingyun Sun
Journal: Bioactive Materials (2022)

As a novel cellular therapy, the anti-inflammatory and immunomodulatory virtues of mesenchymal stem cells (MSCs) make them promising candidates for systemic sclerosis (SSc) treatment. However, the clinical efficacy of this stratagem is limited because of the short persistence time, poor survival, and engraftment of MSCs after injection in vivo. Herein, we develop a novel MSCs-laden injectable self-healing hydrogel for SSc treatment. The hydrogel is prepared using N, O-carboxymethyl chitosan (CS-CM) and 4-armed benzaldehyde-terminated polyethylene glycol (PEG-BA) as the main components, imparting with self-healing capacity via the reversible Schiff-base connection between the amino and benzaldehyde groups. We demonstrate that the hydrogel laden with MSCs not only promoted the proliferation of MSCs and increased the cellular half-life in vivo, but also improve their immune-modulating functions. The tube formation assay indicates that the MSCs could significantly promote angiopoiesis. Moreover, the MSCs-laden hydrogel could inhibit fibrosis by modulating the synthesis of collagen and ameliorate disease progression in SSc disease model mice after subcutaneous injection of bleomycin. All these results highlight this novel MSCs-laden hydrogel and its distinctive functions in treatment of chronic SSc, indicating the additional potential to be used widely in the clinic.